Can a smart sensor keep heart failure patients out of the hospital?

NCT ID NCT07045298

Not yet recruiting Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests whether using a real-time continuous glucose monitor (CGM) can improve blood sugar control and reduce hospital readmissions in people with type 2 diabetes and acute heart failure. Researchers will follow 140 adults during their hospital stay and for three months after discharge, comparing CGM to standard finger-stick testing. The goal is to see if better glucose monitoring can prevent dangerous blood sugar swings and lower the risk of returning to the hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FreeStyle Libre 2 continuous glucose monitor (CGM)
What this could lead to: If successful, this could show that real-time CGM helps people with type 2 diabetes and heart failure avoid dangerous blood sugar swings and reduce repeat hospital visits.
What could go wrong: This is a small, early-stage study (140 participants) that has not yet started. It focuses on monitoring, not a new drug, so the impact on hospital readmissions may be modest or unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure diabetes mellitus heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS HEART FAILURE

Contacts and locations

Locations

Grady Health System

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.